Affiliation: Fred Hutchinson Cancer Research Center
Radich J. Structure, function, and resistance in chronic myeloid leukemia. Cancer Cell. 2014;26:305-306 pubmed publisher
..In this issue of Cancer Cell, Zabriskie and colleagues study how structural changes caused by compound mutations cause clinically relevant changes in TKI sensitivity. ..
Radich J, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al
. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006;103:2794-9 pubmed
..These studies point to specific gene pathways that might be exploited for both prognostic indicators as well as new targets for therapy. ..
Egan D, Radich J. Prognosis and Molecular Monitoring in Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2015;15 Suppl:S109-13 pubmed publisher
..Expert guidelines that incorporate definitions and milestones of response are referenced to aid in clinical decision-making. ..
Radich J. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001;15:21-36 pubmed
..For those without a donor, following the disease by PCR-based techniques may detect early relapse. For relapsed patients without the option of transplantation, investigative studies are appropriate...
Radich J. How I monitor residual disease in chronic myeloid leukemia. Blood. 2009;114:3376-81 pubmed publisher
..This article will try to address these issues by describing how I monitor CML, which, in summary, is with interest and without panic...
Radich J, Kopecky K, Appelbaum F, Kamel Reid S, Stock W, Malnassy G, et al
. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012;120:3898-905 pubmed publisher
..In summary, DAS compared with IM appeared to have more short-term cytogenetic and molecular response, more hematologic toxicity, and similar overall survival. This trial is registered at www.clinicaltrials.gov as NCT00070499...